Favipiravir

Our partnership with Japan's Fujifilm Toyama Chemical, innovators of Favipiravir, will enable us to make the product accessible to COVID-19 patients around the world. Favipiravir is an oral antiviral drug that works by inhibiting the multiplication of the infection-causing virus, thus decreasing the viral load in the body.

The treating physician should be consulted before taking the drug. Also, women who are breastfeeding/pregnant, and people suffering from any liver or kidney problems should avoid taking this medicine. We recommend informing the physician of a history of hypersensitivity and uric acid metabolism abnormalities, or gout.

Remdesivir

We have partnered with US company Gilead Sciences, innovators of Remdesivir, to make the product available for COVID-19 patients globally. Remdesivir is an injectable antiviral drug that stops the multiplication of the infection-causing virus, thereby decreasing the body's viral load.

This drug is to be used in hospitalised adults and children aged 12 years and older who weigh at least 40 kg. We recommend consulting the treating physician before taking the drug. Also, women who are breastfeeding/pregnant, and people suffering from any liver or kidney problems, should avoid taking this medicine. We recommend informing the physician of a history of hypersensitivity and uric acid metabolism abnormalities, or gout.

Molnupiravir

We have collaborated with American company Merck & Co, innovators of Molnupiravir, to make the product accessible to COVID-19 patients around the world. Molnupiravir is an investigational oral antiviral drug that inhibits the multiplication of the infection-causing virus, thereby decreasing the viral load in the body. It is currently undergoing Phase 3 clinical studies globally for treating mild to moderate COVID-19.

Baricitinib

Our partnership with the US-based Eli Lilly and Company, innovators of Baricitinib, will enable us to bring the product to India. Baricitinib is an oral drug that reduces the body's unwanted inflammatory response to COVID-19. It also prevents the entry of the virus causing the disease into cells.

The drug Baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with Remdesivir for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).